What is the Impact Factor of Clinical Lymphoma Myeloma & Leukemia?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Clinical Lymphoma Myeloma & Leukemia is 4.10, ranking in quartile Q1 of Web of Science (SCIE).

Is Clinical Lymphoma Myeloma & Leukemia indexed in Web of Science or Scopus?

Yes, Clinical Lymphoma Myeloma & Leukemia is indexed in Web of Science (SCIE, Q1 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.615 (Q2) and an H-index of 71.

Who publishes Clinical Lymphoma Myeloma & Leukemia and what is the Article Processing Charge (APC)?

Clinical Lymphoma Myeloma & Leukemia is published by Cancer Media Group. The estimated Article Processing Charge (APC) is approximately $3,068 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Clinical Lymphoma Myeloma & Leukemia?

The official ISO-4 abbreviation of Clinical Lymphoma Myeloma & Leukemia is "CL LYMPH MYELOM LEUK" with common acronym "clml". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q1Scopus Q2SCImago #9,568Hybrid

Clinical Lymphoma Myeloma & Leukemia

Acronym:clml

•

Abbreviation (ISO):CL LYMPH MYELOM LEUK

•

Identifier (ISSN):2152-2650(Print)/2152-2669(Online)

•

Publisher:Cancer Media Group

Official Website Submission Portal Compare

Clarivate IF (2026)

4.1↑ +1.4

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Clinical Lymphoma Myeloma & Leukemia

WoS Q1

Annual Impact Factor Metric

Current (2026):4.1

Scopus SJR & RankScopus Q2

0.615

#9,568

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

71 papers with at least that number of citations each

WoS: SCIE / JCRQ1

Self-Citation Rate3.7%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

230articles/year

23.66% Gold OA•73.12% Original Research

Aims & Scope

Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

Topics Covered (Recognized by AI)

MedicineBiologyInternal MedicineImmunologyGeneticsPathologyOncologySurgeryChemistryBiochemistryCancer ResearchCell Biology

Primary Research Areas

Oncology Hematology

Official Website NLM PubMed Catalog Submission Portal SCImago Profile 1 Calls for Papers

1 calls

Special Issues

Calls for Papers

1 Calls for Papers · Automatically synced from ScienceDirect & publishers

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

HEMATOLOGY

Rank25/103

IndexSCIE

JCRSCIE2026

ONCOLOGY

Rank111/333

IndexSCIE

JCISCIE2026

HEMATOLOGY

Rank46/103

IndexSCIE

JCISCIE2026

ONCOLOGY

Rank196/333

IndexSCIE

Category	Index	Rank	Quartile
HEMATOLOGY	JCRSCIE	25/103	Q1
ONCOLOGY	JCRSCIE	111/333	Q2
HEMATOLOGY	JCISCIE	46/103	Q2
ONCOLOGY	JCISCIE	196/333	Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF4.1

Articles / Year3,826

Total Citations47

2025

IF2.7

Articles / Year3,476

Total Citations735

2024

IF2.7

Articles / Year2,200

Total Citations1,461

2023

IF2.7

Articles / Year2,000

Total Citations1,664

2022

IF2.822

Articles / Year1,575

Total Citations1,885

Year	Impact Factor	Articles / Year	Total Citations
2026	4.1	3,826	47
2025	2.7	3,476	735
2024	2.7	2,200	1,461
2023	2.7	2,000	1,664
2022	2.822	1,575	1,885
2021	3.231	1,396	3,378
2020	2.298	702	3,778
2019	2.274	1,264	4,808
2018	2.308	547	3,841
2017	—	859	4,017
2016	—	364	2,978
2015	—	1,008	3,677

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #9,568Scopus Q2SCImago Profile

Scopus Coverage:2010-2026

•

Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicine

Scopus Citation Rank (SJR)Q2

0.615

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

2.70

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,068 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,413

3-Year Documents1,077

Citable Documents1,052

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)2

Citations in government and international policy documents

Female Author Rate41.3%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

HematologyQ2

Cancer ResearchQ3

OncologyQ3

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 3.7%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

4区ONCOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Clinical Lymphoma Myeloma & Leukemia (acronym: clml, abbr: CL LYMPH MYELOM LEUK, ISSN: 2152-2650) is a peer-reviewed international scholarly journal in the field of ONCOLOGY, published by Cancer Media Group in United States since 2010. The periodical holds a Journal Impact Factor (JIF) of 4.10, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 0.615 (Q2), an H-index of 71.

The journal enforces rigorous peer evaluation with a publication frequency of Bimonthly, an annual output of approximately 230 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,068 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.